Category Archives: biotech

Watch biotech startups pitch at IndieBio’s demo day today

IndieBio, the biotech startup accelerator that’s produced heaps of notable companies (including several that have graced the Startup Battlefield), is holding its twice-annual demo day today at 3PM Pacific Time. An even dozen young companies will be pitching their work, from AI-informed research to artificial meat, and you can watch them present live right here. The IndieBio program is a four-month one that takes companies at the seed stage, often researchers straight out of graduate programs or university research groups, and gets them into shape for a […]

Read more

China is funding the future of American biotech

Silicon Valley is in the midst of a health craze, and it is being driven by “Eastern” medicine. It’s been a record year for US medical investing, but investors in Beijing and Shanghai are now increasingly leading the largest deals for US life science and biotech companies. In fact, Chinese venture firms have invested more this year into life science and biotech in the US than they have back home, providing financing for over 300 US-based companies, per Pitchbook. That’s the story at Viela Bio, a Maryland-based company exploring treatments […]

Read more

uBiome is jumping into therapeutics with a healthy $83 million in Series C financing

23andMe, IBM and now uBiome is the next tech company to jump into the lucrative multi-billion dollar drug discovery market. The company started out with a consumer gut health test to check whether your intestines carry the right kind of bacteria for healthy digestion but has since expanded to include over 250,000 samples for everything from the microbes on your skin to vaginal health — the largest data set in the world for these types of samples, according to the company. Founder Jessica Richman now says there’s […]

Read more

George Church’s genetics on the blockchain startup just raised $4.3 million from Khosla

Nebula Genomics, the startup that wants to put your whole genome on the blockchain, has announced the raise of $4.3 million in Series A from Khosla Ventures and other leading tech VC’s such as Arch Venture Partners, Fenbushi Capital, Mayfield, F-Prime Capital Partners, Great Point Ventures, Windham Venture Partners, Hemi Ventures, Mirae Asset, Hikma Ventures and Heartbeat Labs. Nebula has also has forged a partnership with genome sequencing company Veritas Genetics. Veritas was one of the first companies to sequence the entire human genome for less than $1,000 in 2015, later […]

Read more

RDMD attacks rare diseases with data mined from health records

You wouldn’t expect a medical app to get its start as a Snapchat competitor. Neither did video chat startup TapTalk’s founder Onno Faber. But four years ago he was diagnosed with a rare disease called neurofibromatosis type 2 that caused tumors, leading Onno to lose hearing in one ear. He’s amongst the one in 10 people with an uncommon health condition suffering from the lack of data designed to invent treatments for their ails. And he’s now the co-founder of RDMD. Emerging from stealth today, RDMD aggregates and analyzes medical […]

Read more

Cytera CellWorks aims to bring cell culture automation to your dinner plate

Cytera CellWorks hopes to revolutionize the so-called “clean meat” industry through the automation of cell cultures — and that could mean one day, if all goes to plan, the company’s products could be in every grocery store in America. Cytera is a ways off from that happening, though. Founded in 2017 by two college students in the U.K., Ignacio Willats and Ali Afshar, Cytera uses robotic automation to configure cell cultures used in things like growing turkey meat from a petri dish or testing stem cells. The two […]

Read more

Zbiotics says it’s bioengineered a hangover cure

Y Combinator backed Zbiotics has spend two years developing what they’re billing as the world’s first genetically engineered probiotic. The startup’s initial product isn’t exactly world-changing but it might just save your day — given they’ve invented an elixir of ‘next day’ life: Aka a hangover cure. Although you actually have to take it before — or, well, during — drinking rather than waiting until the moment of regretful misery when you wake up. How have they done this? For their first product they’ve bioengineered probiotic bacteria to produce more of […]

Read more

While tech waffles on going public, biotech IPOs boom

For people who make investment decisions based on revenues and projected earnings, biotech IPOs are kind of a non-starter. Not only are new market entrants universally unprofitable, most have zero revenue. Going public is mostly a means to raise money for clinical trials, with red ink expected for years to come. That pattern may be one reason the venture capital press, Crunchbase News included, tends to devote a disproportionately small portion of coverage to biotech IPOs. It’s more exciting to watch a big-name internet company pop in first-day trading or poke fun at […]

Read more